Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion

CNBC Published Updated Stocks
Sign in to save

Affected assets and topics

SHARES

Expected market reaction

Bullish Confidence 60% How confidence is read Horizon: Short term Impact: Low

Evidence trail

Evidence
Source CNBC
Claim Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion
AI inference Bullish · 60%
Generated 2026-05-29 03:10

AI provenance

Analysed by Rule-Based Analysis not AI Methodology v1.0 Generated
Technical identifiers
Provider tag
free-analysis-rule-based-analysis
Analysis version
free-analysis-rule-based-analysis
Article id
89209

Original source

Innovent Biologics rose as much as 10%, after entering a strategic global licensing and collaboration agreement with Pfizer to develop oncology medicines.

Read the full article on CNBC

Original article published by CNBC on May 29, 2026. Analysis and insights provided by AnalystMarkets AI.

Related coverage

This model on similar stories

Rule-Based Analysis · 34.2% correct across 732 scored calls on equities See the full record